BNTC Stock Overview
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Benitec Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.06 |
| 52 Week High | US$9.01 |
| 52 Week Low | US$1.86 |
| Beta | 0.98 |
| 1 Month Change | -13.80% |
| 3 Month Change | 3.73% |
| 1 Year Change | -12.20% |
| 3 Year Change | -93.62% |
| 5 Year Change | -99.41% |
| Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable
Nov 30
Benitec Biopharma prices of $18M securities offering
Sep 13Benitec GAAP EPS of -$2.23, revenue of $0.07M
Sep 02We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate
Jan 13We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully
Sep 30Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?
May 12Benitec Bio secures $13M capital via equity offering
Apr 28Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?
Jan 27How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?
Dec 02Shareholder Returns
| BNTC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.8% | 0.5% | 0.09% |
| 1Y | -12.2% | -8.9% | 10.4% |
Return vs Industry: BNTC underperformed the US Biotechs industry which returned -7.1% over the past year.
Return vs Market: BNTC underperformed the US Market which returned 13.3% over the past year.
Price Volatility
| BNTC volatility | |
|---|---|
| BNTC Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BNTC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: BNTC's weekly volatility has decreased from 20% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 17 | Jerel Banks | https://benitec.com |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Benitec Biopharma Inc. Fundamentals Summary
| BNTC fundamental statistics | |
|---|---|
| Market Cap | US$7.85m |
| Earnings (TTM) | -US$20.42m |
| Revenue (TTM) | US$75.00k |
105.0x
P/S Ratio-0.4x
P/E RatioIs BNTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNTC income statement (TTM) | |
|---|---|
| Revenue | US$75.00k |
| Cost of Revenue | -US$106.00k |
| Gross Profit | US$181.00k |
| Other Expenses | US$20.60m |
| Earnings | -US$20.42m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.94 |
| Gross Margin | 241.33% |
| Net Profit Margin | -27,230.67% |
| Debt/Equity Ratio | 0% |
How did BNTC perform over the long term?
See historical performance and comparison